Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...

Pfizer is one of the world's largest pharmaceutical companies. Even after losing more than half of its value, it still has a ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...

By Yadarisa Shabong Jan 20 (Reuters) - Britain's GSK and Japan's Shionogi said on Tuesday that Pfizer will exit their HIV ...

The pharmaceutical industry says a popular class of targeted cancer therapies could one day replace chemotherapy and its potential for harsh side effects. There is still more work to be done to refine ...

Connecticut-based Pfizer Inc. said Thursday that it has completed the successful acquisition of Metsera, Inc., which is “a clinical-stage biopharmaceutical company accelerating the next generation of ...

Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong leadership positions in distinct therapeutic areas. NVO is widely recognized ...

Pfizer's coronavirus-related sales have fallen sharply -- and they may decline even further next year. The company is developing some promising products, including a flu vaccine and a weight loss ...

Pfizer's stock soared during the coronavirus pandemic because of its COVID-19 vaccine. The world has learned to live with the coronavirus, and Pfizer's stock has plunged as a result. Faced with patent ...